Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is a type of adoptive cell transfer or immunotherapy that uses genetically modified T-cells to find and kill cancer cells. In CAR T-cell therapies, T cells are taken from the patient’s blood and are changed in the lab by adding a gene for a man-made receptor (called a chimeric antigen receptor or CAR). This helps them better identify specific cancer cell antigens. The CAR T cells are then given back to the patient.
The advantages of CAR T-cell therapy is the short treatment time needed – administered with a single infusion that may require at the most, two weeks of inpatient care, and then it’s done. Because aggressive chemotherapy is not used, most patients have a much more rapid recovery than after stem cell transplants in which aggressive chemotherapy is used. At some point in the future, CAR T-cell therapy may even replace most types of transplants but at the current time, CAR T-cell therapy is approved for the treatment of patients in whom transplant is not likely to be curative or in patients who relapse after transplant.
For More Details, Grab the Sample PDF: https://www.360marketupdates.com/enquiry/request-sample/21008170&piyush
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, target antigen, and region. The global market for CAR T-cell therapy can be segmented by product: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. The Yescarta segment held the largest share of the global CAR T-cell therapy market in 2021 and is anticipated to hold its share during the forecast period. CAR T-cell therapy market is further segmented by target antigen: CD19/CD22, BCMA (B-cell maturation antigen), others. Based on region, the CAR T-cell therapy market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). North America was the largest contributor to the global CAR T-cell therapy market in 2021.
Top Key Companies of this Sector:
AbbVie Inc., Amgen Inc., AstraZeneca plc, Autolus Therapeutics plc, Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Co., Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology S.A., Editas Medicine, Inc., Fortress Biotech Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Legend Biotech Corporation, Mustang Bio, Inc., Novartis International AG, Pfizer Inc., PureTech Health plc, Servier Laboratories Ltd., Takeda Pharmaceutical Company Limited, among others.